New octreotide pill faces off against current capsule in healthy volunteer study
NCT ID NCT07663318
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-stage trial in 18 healthy adults compares a new octreotide tablet (T25) with an existing capsule (MYCAPSSA) to see how much drug gets into the blood. It also checks whether a high-fat meal changes absorption of the tablet. Participants take single doses under fasting or fed conditions, and blood samples are collected over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- octreotide acetate
- What this could lead to
- If successful, this could help develop a more convenient oral form of octreotide for people with acromegaly.
- What could go wrong
- This is a very early Phase 1 study in only 18 healthy people, so results may not apply to patients or predict long-term effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Growth-Hormone blocker stay safe in everyday use? a korean study investigates
- Which intubation method works best for acromegaly patients?
- New software could improve acromegaly care
- New drug MAR002 aims to tame acromegaly in early trial
- Scientists hunt for hidden genes behind pituitary tumors
- New study tracks Octreotide's Real-World impact on acromegaly over two years